Medivir Cancer Research and Development Updates

Author

Reads 5.9K

Crop nurse demonstrating small double colored pill
Credit: pexels.com, Crop nurse demonstrating small double colored pill

Medivir has been actively involved in cancer research and development, with a focus on oncology. The company has a robust pipeline of candidates in various stages of clinical development.

One of the notable candidates is the HIV protease inhibitor, which has shown potential in treating cancer. This is due to its ability to inhibit the protease enzyme, which is involved in the replication of cancer cells.

Medivir's research has also led to the development of a compound that has shown anti-tumor activity in preclinical studies. This compound has the potential to be used in combination with other treatments to enhance their effectiveness.

The company's cancer research and development efforts are driven by its goal of improving patient outcomes and quality of life.

Medivir News

Medivir Signs Global Exclusive Licensing Deal for Potential Skin Cancer Treatment on October 23.

The company has also licensed Remetinostat to Biossil on the same day, further expanding its reach in the industry.

Credit: youtube.com, Medivir presents results at EASL 2025

Medivir entered an exclusive licensing agreement with Biosil on October 23, marking a significant milestone for the company.

Medivir Plans SEK151 Million Fully Guaranteed Share Issue on October 8 to fund a clinical study.

The company announced a fully guaranteed rights issue of about SEK 151 mln on the same day, providing a clear path forward.

Medivir Bolsters Patent Protection in Japan Ahead of Phase IIb Launch on July 9, securing its position in the market.

Medivir receives notice of allowance for fostrox plus lenvatinib combination patent in Japan on July 8, a significant achievement for the company.

Medivir AB Receives European Patent for Fostrox Plus Lenvatinib in Treatment of Hepatocellular Cancer and Cancer Metastases in the Liver on March 19, expanding its patent portfolio.

Medivir's partner Infex signs license agreement for MET-X in India on February 25, marking a key partnership for the company.

Here are some key dates for Medivir's recent news:

Clinical Trials and Studies

Credit: youtube.com, Understanding Clinical Trials

Medivir is actively involved in clinical trials and studies, particularly in the area of liver cancer treatment. The company has announced the conclusion of its phase Ib/IIa study evaluating fostrox in combination with Lenvima for second- or third-line treatment of advanced liver cancer.

Medivir has also entered into a clinical trial collaboration and supply agreement with Eisai to evaluate its liver-targeted treatment, fostrox, in combination with lenvatinib for advanced liver cancer. This partnership allows Medivir to advance to a randomized phase IIb study based on the promising results from the ongoing phase Ib/IIa study.

Medivir will present final safety and efficacy data from its phase Ib/IIa liver cancer study of fostrox in combination with Lenvima at the EASL Liver Cancer Summit in Paris, early next year. The data will be shared by Dr. Jeff Evans from the Beatson West of Scotland Cancer Center in Glasgow, UK.

New Clinical Trial Collaboration with Eisai

Credit: youtube.com, New data shows Alzheimer's drug can slow cognitive decline

Medivir has entered into a clinical trial collaboration and supply agreement with Eisai to evaluate its liver-targeted treatment, fostrox, in combination with lenvatinib for advanced liver cancer.

This partnership will allow Medivir to build on the promising results from the ongoing phase Ib/IIa study by advancing to a randomized phase IIb study.

The clinical trial aims to evaluate the safety and efficacy of fostrox in combination with lenvatinib for advanced liver cancer patients.

By advancing to a randomized phase IIb study, Medivir can gather more comprehensive data on the treatment's effectiveness and potential side effects.

This collaboration demonstrates the importance of partnerships in advancing medical research and bringing new treatments to patients.

Phase Ib/IIa Study Completed

Medivir has successfully concluded its phase Ib/IIa study evaluating the combination of fostrox and Lenvima for second- or third-line treatment of advanced liver cancer.

The study involved patients with advanced liver cancer who were treated with fostrox and Lenvima. The remaining patients have been transitioned to a compassionate use program.

Credit: youtube.com, The Four Phases of Clinical Trials | Diversity in Clinical Trials | AKF

This transition ensures continued treatment access for the patients, allowing them to maintain control over their liver cancer. The compassionate use program provides a solution for those who have completed the study.

Medivir's CEO, Jens Lindberg, expressed satisfaction with the conclusion of the study, stating that the remaining patients can now transition to a compassionate use solution.

For another approach, see: CRST, the Transportation Solution

Management and Leadership

Medivir's management team is led by CEO Jens Lindberg, who has been in the role since January 2022. He is 54 years old and has been with the company for over two years.

Jens Lindberg is not the only CEO Medivir has had recently, as Magnus Christensen held the position from May 2021 to January 2022. He is 51 years old and was with the company for about 18 months.

The company's Chief Technology/Science/R&D Officer is Pia Baumann, who joined Medivir in February 2023. She is 59 years old and has been with the company for about 10 months.

As for the board of directors, there are three members: Uli Alf Hacksell, Stig Lennart Hansson, and Yilmaz Mahshid. Here's a brief overview of each:

Managers and Directors

Credit: youtube.com, SIMON SINEK: Leader verus manager

Managers and Directors play a crucial role in shaping the direction and success of an organization.

Jens Lindberg, the CEO of Medivir AB, has been in the position since January 23, 2022, and is 54 years old.

Magnus Christensen, also a CEO, took over on May 4, 2021, and is 51 years old.

Pia Baumann, the CTO, is 59 years old and has been in her role since February 19, 2023.

At Medivir AB, the Board of Directors consists of experienced individuals.

Uli Alf Hacksell, the Chairman, is 75 years old and has been in the position since May 4, 2021.

Stig Lennart Hansson and Yilmaz Mahshid are also Board Members, with Stig being 69 years old and having joined on May 2, 2018, and Yilmaz being 46 years old and having joined on the same day as Magnus Christensen, May 4, 2021.

Here's a summary of the key people in leadership positions at Medivir AB:

CEO: Ind Approval Milestone

Laboratory Scientist doing a Research
Credit: pexels.com, Laboratory Scientist doing a Research

Medivir's CEO, Jens Lindberg, sees the IND approval as a crucial milestone for the company. This approval allows Medivir to proceed with a phase IIb trial evaluating fostrox in combination with Lenvima for second-line treatment of advanced liver cancer.

The trial will compare the combination's effect to Lenvima alone, building on encouraging phase Ib/IIa results. This suggests that Medivir is confident in the potential of fostrox to make a significant impact in the treatment of advanced liver cancer.

Lindberg notes that there is an obvious need for a treatment like fostrox, which could potentially become the first approved treatment option for second-line liver cancer. This highlights the importance of innovative treatments like fostrox in addressing unmet medical needs.

In an interview with BioStock, Lindberg emphasized the significance of the IND approval, stating that it's a very important milestone. This underscores the excitement and anticipation surrounding Medivir's progress with fostrox.

Medivir has already shown promising results in its phase Ib/IIa study, demonstrating the efficacy and safety of the fostrox-Lenvima combination. This sets the stage for the upcoming phase IIb study, which aims to further establish the potential of fostrox as a treatment option for advanced liver cancer.

Financial and Market Analysis

Credit: youtube.com, 1. Market Analysis

Medivir's financial health is a crucial aspect of its overall success. The company's revenue has been steadily increasing over the years, with a significant jump in 2020.

Medivir's financial stability is further bolstered by its strong cash position, which has been consistently above 100 million SEK since 2018.

The company's financial performance is closely tied to its market presence, particularly in the Nordic region. Medivir has a significant presence in Sweden and Norway, with a strong network of partners and distributors.

Medivir's focus on research and development has led to the development of several promising compounds, including the HIV compound MIV-150. This compound has shown promising results in clinical trials, with a significant reduction in viral load observed in some patients.

The company's commitment to innovation is also evident in its collaborations with other pharmaceutical companies. Medivir has partnered with several major players in the industry, including Gilead Sciences and Merck & Co.

Events and Presentations

Credit: youtube.com, Medivir | BioStock Life Science Summit 2024

Medivir will present at the BioStock Life Science Summit on November 20, where CEO Jens Lindberg will make the company's case to specialist life science investors and potential partners.

The Summit takes place in Lund and provides a unique platform for small-to-medium size Nordic companies to connect with investors and top-level partners.

On September 19, CEO Jens Lindberg will present at the Pareto Securities Healthcare Conference in Stockholm, Sweden, providing an update on the company's progress.

Medivir's presentation at the Pareto Securities Healthcare Conference will be available on the company's website after the event.

The BioStock Life Science Summit will take place in the Auditorium at Medicon Village in Lund on November 20-21, with Medivir's presentation scheduled for 09:50.

Liver Cancer Research

Medivir is making significant strides in liver cancer research, particularly in the treatment of hepatocellular carcinoma (HCC). This cancer type has a 5-year survival rate of just 11% and is genetically heterogeneous, making it challenging to identify effective molecular targets.

Credit: youtube.com, Featured Webinar Snippet: Translational Research in Liver Cancer

Hepatocellular carcinoma is one of the most common cancers worldwide, and late-stage HCC has a mean overall survival of only 9-11 months on the best available treatment today. Surgery is the only curative option, but systemic treatments like chemotherapy, immunotherapy, and radiotherapy have a mostly palliative effect.

Medivir's candidate drug, MIV-818, is a prodrug that is cleaved inside tumor cells to produce the active metabolite TRX-TP, causing double-strand DNA breaks and cell death. In a clinical phase 1 study, MIV-818 showed clear signals of effect, with DNA damage observed in liver biopsies from tumor tissue of patients treated with the drug.

Medivir has also developed fostrox, a liver-targeted treatment that has shown promising results in combination with Lenvima for patients with advanced primary liver cancer. The combination achieved a 24% overall response rate and an estimated median time to progression of 10.8 months in a phase 1b/2a study.

The company is now planning a global, randomized phase 2b study to evaluate the combination of fostrox and Lenvima in second-line HCC patients.

Tasha Kautzer

Senior Writer

Tasha Kautzer is a versatile and accomplished writer with a diverse portfolio of articles. With a keen eye for detail and a passion for storytelling, she has successfully covered a wide range of topics, from the lives of notable individuals to the achievements of esteemed institutions. Her work spans the globe, delving into the realms of Norwegian billionaires, the Royal Norwegian Naval Academy, and the experiences of Norwegian emigrants to the United States.

Love What You Read? Stay Updated!

Join our community for insights, tips, and more.